Skip to Content

Label Changes for:

Maxipime (cefepime hydrochloride) 500 mg, 1g, 2g per vial powder for injection

September 2009

Changes have been made to the PRECAUTIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- September 2009


Information for Patients
  • Patients should be advised of neurological adverse events that could occur with Maxipime use. Patients should be instructed to inform their healthcare provider at once of any neurological signs and symptoms including encephalopathy (disturbance of consciousness including confusion, hallucinations, stupor, and coma), myoclonus and seizures for immediate treatment, dosage adjustment, or discontinuation of Maxipime.